Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Respirology (Carlton, Vic.)|August 21, 2010
Targeted therapy: an evolving world of lung cancerKwok-Chi Lam, Tony S MokThoracic Cancer|September 19, 2017
Management of malignant pleural effusion: Options and recommended approachesLinda Leung, Michael Hsin, Kwok Chi LamJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?Tony Mok, Jin-Ji Yang, Kwok-Chi LamOncology|July 16, 2005
Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancerTony S K Mok, Kwok Chi Lam, Conrad Lee, et al.Investigational New Drugs|September 14, 2007
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cellsBrigette Ma, Boon Cher Goh, Eng Huat Tan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2007
Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancerTony S K Mok, Simon Ho, Gong Chan, et al.Future Oncology (London, England)|January 30, 2018
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapiesFederico Cappuzzo, Ross Soo, Maximilian Hochmair, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2010
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptorsChia-Chi Lin, Hsin-Hsin Hsu, Chia-Tung Sun, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2011
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)Sumitra Thongprasert, Emma Duffield, Nagahiro Saijo, et al.Lung Cancer (Amsterdam, Netherlands)|February 24, 2020
ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKIOscar S H Chan, Kwok Chi Lam, Jacky Y C Li, et al.Pageof 2